A detailed history of Continuum Advisory, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Continuum Advisory, LLC holds 11 shares of KRYS stock, worth $1,971. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11
Previous 15 26.67%
Holding current value
$1,971
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$156.64 - $199.61 $626 - $798
-4 Reduced 26.67%
11 $1,000
Q3 2024

Nov 15, 2024

BUY
$174.7 - $213.66 $698 - $854
4 Added 36.36%
15 $2,000
Q1 2024

May 10, 2024

BUY
$108.01 - $179.35 $1,188 - $1,972
11 New
11 $1,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.6B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Continuum Advisory, LLC Portfolio

Follow Continuum Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Continuum Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Continuum Advisory, LLC with notifications on news.